Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBITDA (2016 - 2025)

Historic EBITDA for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to -$6.5 million.

  • Integra Lifesciences Holdings' EBITDA rose 6152.89% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$483.5 million, marking a year-over-year decrease of 61198481.01%. This contributed to the annual value of $28.4 million for FY2024, which is 7452.52% down from last year.
  • Integra Lifesciences Holdings' EBITDA amounted to -$6.5 million in Q3 2025, which was up 6152.89% from -$490.9 million recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' EBITDA registered a high of $75.8 million during Q1 2021, and its lowest value of -$490.9 million during Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' median EBITDA value was $28.7 million (recorded in 2021), while the average stood at -$99052.6.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 252383.56% in 2021, then crashed by 229661.17% in 2025.
  • Integra Lifesciences Holdings' EBITDA (Quarter) stood at $58.2 million in 2021, then grew by 16.52% to $67.8 million in 2022, then plummeted by 46.86% to $36.0 million in 2023, then decreased by 1.17% to $35.6 million in 2024, then plummeted by 118.17% to -$6.5 million in 2025.
  • Its EBITDA stands at -$6.5 million for Q3 2025, versus -$490.9 million for Q2 2025 and -$21.8 million for Q1 2025.